• 1
    Talley NJ, Colin-Jones D, Koch KL, Koch M, Nyrén O, Stanghellini V. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 14560.
  • 2
    Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45(Suppl. 2): II3742.
  • 3
    Talley NJ. Review article: functional dyspepsia — should treatment be targeted on disturbed physiology? Aliment Pharmacol Ther 1995; 9: 10715.
  • 4
    Holtmann G, Talley NJ. Functional dyspepsia. Current treatment recommendations. Drugs 1993; 45: 91830.
  • 5
    Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 134: 3619.
  • 6
    Talley NJ, McNeil D, Hayden A, Piper DW. Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Gastroenterology 1986; 91: 14956.
  • 7
    Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind randomised placebo-controlled trials. Aliment Pharmacol Ther 1998; 12: 105565.
  • 8
    Finney JS, Kinnersley N, Hughes M, O'Bryan-Tear CG, Lothian J. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998; 26: 31220.
  • 9
    Dobrilla G, Comberlato M, Steele A, Vallaperta P. Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 1989; 11: 16977.
  • 10
    Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia. a meta-analysis. Am J Gastroenterol 2001; 96: 68996.
  • 11
    Lasser RB, Bond JH, Levitt MD. The role of intestinal gas in functional abdominal pain. N Engl J Med 1975; 293: 5246.
  • 12
    Serra J, Azpiroz F, Malagelada J-R. Intestinal gas dynamics and tolerance in humans. Gastroenterology 1998; 115: 54250.
  • 13
    Mearin F, Cucala M, Azpiroz F, Malagelada JR. The origin of symptoms on the brain–gut axis in functional dyspepsia. Gastroenterology 1991; 101: 9991006.
  • 14
    Stanghellini V, Tosetti C, Paternico A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996; 110: 103642.
  • 15
    Holtmann G, Gschossmann J, Karaus M, et al. Randomised double-blind comparison of simethicone and cisapride in functional dyspepsia. Aliment Pharmacol Ther 1999; 13: 145964.DOI: 10.1046/j.1365-2036.1999.00644.x
  • 16
    Holtmann G, Goebell H, Holtmann M, Talley NJ. Dyspepsia in healthy blood donors: pattern of symptoms and association with Helicobacter pylori. Dig Dis Sci 1994; 39: 10908.
  • 17
    Holtmann G, Goebell H, Talley NJ. Dyspepsia in consulters and non-consulters: prevalence, health-care seeking behaviour and risk factors. Eur J Gastroenterol Hepatol 1994; 6: 91724.
  • 18
    Agreus L, Svärdsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 67180.
  • 19
    Bytzer P, Hansen JM, Rune S, et al. Identifying responders to acid suppression in dyspepsia using a random starting day trial. Aliment Pharmacol Ther 2000; 14: 148594.
  • 20
    O'Brien P. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40: 107987.
  • 21
    Lehmacher W, Wassmer G, Reitmeir P. Procedures for two-sample comparisons with multiple endpoints controlling the experimentwise error rate. Biometrics 1991; 47: 51121.
  • 22
    SAS Institute Inc. SAS/STAT Software: Changes and Enhancements through Release 6.12. Cary, NC: SAS Institute, 1997.
  • 23
    SAS Institute Inc. SAS/STAT User Guide, Vols. 1 and 2. Cary, NC: SAS Institute, 1990.
  • 24
    Lifschitz CH, Irving CS, Smith EO. Effect of a simethicone-containing tablet on colonic gas elimination in breath. Dig Dis Sci 1985; 30: 42630.
  • 25
    Smart HL, Atkinson M. Comparison of a dimethicone/antacid (Asilone gel) with an alginate/antacid (Gaviscon liquid) in the management of reflux oesophagitis. J R Soc Med 1990; 83: 5546.
  • 26
    Ansorg R, Von Recklinghausen G, Heintschel VH. Susceptibility of Helicobacter pylori to simethicone and other non-antibiotic drugs. J Antimicrob Chemother 1996; 37: 4552.
  • 27
    Kane AV, Plaut AG. Unique susceptibility of Helicobacter pylori to simethicone emulsifiers in alimentary therapeutic agents. Antimicrob Agents Chemother 1996; 40: 5002.
  • 28
    Ng FH, Wong SY, Kng C, Chow SL, Lai KC, Ng WF. Effect of simethicone on the accuracy of the rapid urease test. Eur J Gastroenterol Hepatol 1998; 10: 8514.
  • 29
    Van Outryve M, De Nutte NEE, Gooris JP. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. Scand J Gastroenterol Suppl 1993; 28: 4753.
  • 30
    Talley NJ, Holtmann G, Agreus L, Jones M. Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: a four nations study. Am J Gastroenterol 2000; 95: 143947.
    Direct Link:
  • 31
    Talley NJ, Weaver AL, Tesmer DL, Zinsmeister AR. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993; 105: 137886.